Skip to content

Umbilical Cord Blood Therapy for Children With Cerebral Palsy

Allogeneic Umbilical Cord Blood Therapy for Children With Cerebral Palsy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01639404
Enrollment
17
Registered
2012-07-12
Start date
2012-07-31
Completion date
2013-03-31
Last updated
2013-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Keywords

Cerebral Palsy, Umbilical Cord Blood, Rehabilitation

Brief summary

This study aims to evaluate the efficacy of umbilical cord blood therapy for children with cerebral palsy.

Detailed description

Cerebral palsy is a disorder of movement and posture resulted from a non-progressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability. Many experimental animal studies have revealed that umbilical cord blood is useful to repair neurological injury in brain. On the basis of many experimental studies, umbilical cord blood is suggested as a potential therapy for cerebral palsy.

Interventions

The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.

All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.

Sponsors

MinYoung Kim, M.D.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 20 Years
Healthy volunteers
No

Inclusion criteria

* Cerebral Palsy with abnormal muscle tone * Gross Motor Function Classification System (GMFCS): I, II, III, IV, V * Willing to comply with all study procedure

Exclusion criteria

* Medical illnesses including pneumonia or renal function at enrollment * Presence of known genetic disease * Presence of drug hypersensitivity which is related to this study remedy * Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up * Decision by the principal investigator when there are unexpected events that may affect the outcomes

Design outcomes

Primary

MeasureTime frameDescription
Changes in Motor PerformanceBaseline - 1 month - 3 monthsGMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0\ 100, Higher value means better motor quality). GMPM scores at each assessment time points will be reported.
Changes in Standardized Gross Motor FunctionBaseline - 1 month - 3 monthsGMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0\ 100 , Higher value means better gross motor function). GMFM scores at each assessment time points will be reported.

Secondary

MeasureTime frameDescription
Changes in Functional Independence in Daily ActivitiesBaseline - 1 month - 3 monthsWeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher scores mean more independent performance in daily activities. Total WeeFIM scores measured at each assessment time points will be reported.
Changes in Visual Perception TestBaseline - 1 month - 3 monthsVisual perception function will be evaluated with one of three measures: DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). All can be scored as percentile rank from 0 to 100. Higher values mean better visual perception ability.
Changes in Cognitive Neurodevelopmental OutcomeBaseline - 1 month - 3 monthsKorean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scales (higher value means better mental function: 0 - worst, 178 - best). K-BSID-II Mental Scale raw scores at each assessment time points will be reported.
Changes in Functional Performance in Daily ActivitiesBaseline - 1 month - 3 monthsPediatric Evaluation of Disability Inventory (PEDI) for assessing functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). We will report 2 scales and 3 domains of each scale: a Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) which are divided respectively into 3 domains: self care, mobility, and social function. Categories of outcome table will be each domain scores measured at each assessment time point.
Changes in Muscle StrengthBaseline - 1 month - 3 monthsSummation of MMT (manual muscle strength test score): summated scores of the manual muscle strength test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 \ 160) Higher scores mean better muscle strength. Categories of outcome table will be summation of MMT scores measured at each assessment time point.
Changes in Motor Neurodevelopmental OutcomeBaseline - 1 month - 3 monthsKorean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scales (higher value means better motor function: 0 - worst, 112 - best). K-BSID-II Motor Scale raw scores at each assessment time points will be reported.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026